Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit

European Journal of Cancer

Volumn 46, Issue 2, 2010, Pages 377-383

  van Leeuwen, Pim J ^a   Connolly, David ^b   Gavin, Anna ^c   Roobol, Monique J ^a   Black, Amanda ^d   Bangma, Chris H ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b BELFAST CITY HOSPITAL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biopsy; Early detection; ERSPC; Metastasis; Mortality; Outcome; Prostate cancer; PSA; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; CLINICAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER;

AGE OF ONSET; AGED; CAUSE OF DEATH; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; NORTHERN IRELAND; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 72449160280     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.09.008     Document Type: Article

References (25)

1. Collin S.M., Martin R.M., Metcalfe C., et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9 5 (2008) 445-452
2. Kvale R., Auvinen A., Adami H.O., et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 99 24 (2007) 1881-1887
3. Bouchardy C., Fioretta G., Rapiti E., et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 123 2 (2008) 421-429
4. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med (2009)
5. Otto S.J., van der Cruijsen I.W., Liem M.K., et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 105 3 (2003) 394-399
6. Ciatto S., Zappa M., Villers A., et al. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 92 Suppl. 2 (2003) 97-100
7. Andriole G.L., Grubb III R.L., Buys S.S., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009)
8. Cuzick J., Edwards R., and Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 16 9 (1997) 1017-1029
9. Roobol M.J., Kerkhof M., Schroder F.H., et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2009)
10. Connolly D., Black A., Gavin A., Keane P.F., and Murray L.J. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation. Cancer Epidemiol Biomarkers Prev 17 2 (2008) 271-278
11. Roobol M.J., and Schroder F.H. European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 92 Suppl. 2 (2003) 117-122
12. De Koning H.J., Blom J., Merkelbach J.W., et al. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 92 Suppl. 2 (2003) 71-78
13. WHO. International statistical classification of diseases and related health problems. Tenth revision (1992), WHO, Geneva p. 1
14. Aalen. Non parametric inference for a family of counting processes. Ann Statist 6 (1978) 701-726
15. Rembold C.M. Number needed to screen: development of a statistic for disease screening. BMJ 317 7154 (1998) 307-312
16. Day NE. Cancer incidence in five continents. Cumulative rate and cumulative risk. IARC Sci Publ 1992(120). p. 862-4.
17. Lu-Yao G., Albertsen P.C., Stanford J.L., Stukel T.A., Walker-Corkery E.S., and Barry M.J. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 325 7367 (2002) 740
18. Bartsch G., Horninger W., Klocker H., et al. Tyrol prostate cancer demonstration project: early detection, treatment, outcome, incidence and mortality. BJU Int 101 7 (2008) 809-816
19. Integraalkankercentrumrotterdam. IKCnet; 2009. http://www.ikcnet.nl/IKR/index.php.
20. WHO. Data and statistics; 2008. http://www.who.int.
21. Otto S.J., Schroder F.H., and de Koning H.J. Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: self-selection bias?. J Med Screen 11 2 (2004) 89-92
22. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 19 (2005) 1977-1984
23. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 6 (2006) 472-479
24. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 9327 (2002) 103-106
25. Wilson J.M., and Jungner Y.G. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 65 4 (1968) 281-393